

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (October 2005), Supplement 2 (October 2005), and Supplement 3 (November 2005) are preceded, respectively, by S1:, S2:, and S3:.

Abbas, N.A., 610
Abbaterusso, C., 120
Abbott, K.C., 720
Abosaif, N.Y., 1038
Abrahamov, A., 837
Acquistapace, I., 897
Aguilera, A., 938
Aguilera, I., 345
Akbostanici, M.C., 1:E13
Aldigier, J.-C., 6:E113
Algur, N., 837
Aljama, P., 68
Allemand, H., 309
Allen, A.S., 642
Allison, J.J., 595
Allon, M., 501
Alvarez-Lara, M.A., 68
Alves-Rodrigues, E.N., 4:E51
Ambühl, P., 529
Andreucci, M.V., 120
Antoniadi, G., 706
Aranda, F.J., 1074
Aranda, P., 1074
Arfe, G., 18
Ariano, R.E., 681
Aroeira, L.S., 938
Avorn, J., 225, 1080
Axelsson, J., 628

Bae, K.T., 1058
Bailie, G.R., 669
Baird, B.C., 537
Bajo, M.A., 938
Bammens, B., 512
Banet, J.F., 52
Bang, H., 812
Bárány, P., 628
Barbutis, K., 706
Barker, J., 501
Barre, P., 799
Barré, P.E., 1088
Barrett, B., 799
Barrio-Lucía, V., 52
Bastani, B., 754
Bauer, E., 903
Bazari, H., 143
Beck, G.J., 455
Becker, G.J., 990
Becker, Y.T., 5:E91
Becker-Cohen, R., 837
Beddu, S., 577
Bellino, D., 320

Berbarie, R.F., 1:li, 1:E1
Berthier-Schaad, Y., 78
Bhagat, G., 780
Bhimani, B., 3:li, 3:E31
Bianchi, S., 45
Bidani, A., 587
Bigazzi, R., 45
Bihorac, A., 908
Binaut, R., 3:E41
Binik, Y.M., 1088
Bircher, G., 387
Blank, G., 440
Bleyer, A.J., 464
Boeschoten, E.W., 925
Bökenkamp, S.l, 5:E71
Bolt, R.J., 5:l, 5:E71
Bonforte, G., 897
Bos, W.J., 925
Boschi, G., 18
Bosi, A., 550
Bossola, M., 371
Bosworth, H.B., 642
Braden, G.L., 560
Bradley, J., 1117
Brancati, C., 18
Brantzen, A.J.W., 1012
Brennan, D.C., 720
Brenner, R.M., 481
Breslau, N.A., 1:li, 1:E1
Brimhall, B.B., 1049
Brown, E.A., 856
Brown, S., 111
Buccianti, G., 897
Buhaescu, I., 173
Buring, J.E., 871
Burkart, J., 464
Burke, G.L., 214
Burroughs, T.E., 720

Caldwell, S., 933
Campese, V.M., 45
Canbakan, B., 1:E13
Cannella, C.A., 669
Cannella, G., 320
Cao, G., 587
Carey, H.B., 1:E5
Carlisle, E., 799
Carlsson, K., 1:E5
Carr, J.J., 464
Carter, J.E., 351
Cassottana, P., 320
Cavalcante, J.L., 270

Centor, R.M., 595
Chapman, A.B., 1058
Charytan, C., 58
Chavers, B.M., 995
Chen, H., 35
Chen, J.-R., 1099
Chen, S.-T., 1099
Cheng, C.-H., 830
Cheung, A.K., 537, 577
Chi, E.M., 481
Chiodini, P., 18
Chiu, Y.-L., 2:E21
Chonchol, M., 58
Chou, S., 1117
Chow, K.-M., 128, 713
Christenson, R., 35
Chu, T.-S., 2:E21
Chung, K.-Y., 128
Cianciaruso, B., 120
Cirami, C., 550
Cirugeda, A., 938
Clase, C.M., 845
Coburn, J.W., 58
Coe, F.L., 263
Cohen, S.S., 863
Cole, E., 529
Cole, E.H., 163
Colindres, R.E., 812
Collins, A.J., 455, 481, 650, 661, 887
Comotti, C., 120
Conte, G., 18
Cooper, R., 587
Coresh, J., 78, 203
Cortese, C.M., 754
Cotsonis, G., 26
Coventry, S., 982
Covic, A., 173
Cowper, S.E., 763
Cox, J.L., 845
Craig, J.C., 774, 970
Craven, T.E., 214
Croker, B., 4:E55
Cross, A.S., 997

Daar, E.S., 290
D'Agati, V., 780
Danese, M.D., 301
Daniel, L., 3:E41
Daram, S.R., 754
Davies, A.H., 856
Dean, B.B., 301
DeCristofaro, V., 897

Decruyenaere, J., 5:E95
 Decupere, M., 5:E75
 deFilippi, C.R., 35
 Deighan, C.J., 1065
 de Jong, P.E., 102
 Dekker, F.W., 925
 Delgado, P., 339
 del Peso, G., 938
 Demadura, T., 919
 de Mutsert, R., 387
 De Nicola, L., 18
 Dennis, V.W., 242
 de Oliveira Marques, F., 957
 DeOreo, P.B., 621
 Derfler, K., 446, 903
 de Sa, D., 351
 DeVecchi, A., 897
 Devins, G.M., 1088
 Dhondt, A., 5:E95
 Diaconita, M., 6:E113
 Diaz, F., 339
 Dingli, D., 278
 Dinitz-Pensy, M., 997
 Dionne, J.M., 351
 Dipchand, C.S., 845
 Dispenzieri, A., 270
 Dixit, A., 3:lxii, 3:E31
 Djurdjev, O., 799
 Dombek, S., 94
 Don, B.R., 820
 Druml, W., 903
 Dubois, R.W., 301
 du Buf-Vereijken, P.W.G., 1012
 du Caillar, G., 233
 Duff, D.R., 982
 Dylan, M.L., 301

Ebben, J.P., 661
 Edwards, M.S., 214
 Ejaz, A.A., 4:E55
 Ekong, E., 309
 Eleftheriadiss, T., 706
 Elia, M., 387
 Elinder, C.-G., 863
 Ellis, M.R., 856
 Ellison, D.H., 356
 El Nahas, A.M., 1038
 Eloot, S., 5:E95
 Elstein, D., 837
 Emmett, M., 1:li, 1:E1
 Engfer, M., 387
 Ensari, A., 1:E13
 Ergün, I., 1:E13
 Ethier, J., 799
 Evans, I.V., 1107
 Evans, M., 863
 Evenepoel, P., 512

Fain, P., 415
 Faini, A., 897
 Fakhouri, F., 3:E41

Falagas, M.E., 1030
 Fallin, M.D., 78
 Fan, Q., 661
 Fanelli, F.R., 371
 Feldman, H.I., 734
 Fellström, B., 529
 Fender, P., 309
 Fenton, S.S.A., 136
 Ferng, S.-H., 1099
 Fervenza, F.C., 270
 Fesler, P., 233
 Fine, A., 681
 Fink, J.C., 35
 Fink, N.E., 78, 1107
 Finkel, K.W., 26
 Fischer, M.A., 1080
 Fischer, M.J., 1049
 Födinger, M., 520
 Fogo, A.B., 2:liii, 2:E17, 573, 982
 Foley, R.N., 995
 Fontes, C.J.F., 4:E51
 Fored, C.M., 863
 Forman, J.P., 143
 Forrest, G.N., 997
 Fouque, D., 387
 Fried, L.F., 214
 Frishberg, Y., 837
 Frutos, M.A., 1074
 Fryzek, J.P., 863
 Fujita, T., 4:E65

Gaber, L.W., 1140
 Gage, B.F., 791
 Ganai, A., 949
 Ganzini, L., 919
 Garganta, C.L., 1:E5
 Gaziano, J.M., 871
 Geddes, C.C., 949
 Gelber, R.P., 871
 Geneidy, A.A., 962
 Genovesi, S., 897
 Gentil, M.A., 345
 Gertz, M.A., 270
 Giannatos, E., 706
 Giannico, G., 2:liii, 2:E17
 Gilbertson, D.T., 887
 Gillen, D.L., 263
 Giungi, S., 371
 Gjertson, D.W., 489
 Glazner, J.E., 1049
 Glickman, J.D., 316
 Glynn, C., 1065
 Gökden, N., 573
 Goldfarb-Rumyantzev, A.S., 537
 Gonzalez, A., 339
 Gonzalez-Escribano, F., 345
 Goshorn, J., 5:E81
 Gourishankar, S., 1117
 Grambow, S.C., 642
 Grande, J.P., 278
 Grantham, J.J., 1058

Greene, T., 242, 455
 Greenland, S., 489
 Griffiths, R.I., 301
 Grisar, J., 520
 Grönhagen-Riska, C., 529
 Gross, E., 94
 Grünfeld, J.-P., 3:E41
 Guay-Woodford, L.M., 1058
 Guidi, S., 550
 Guo, H., 887
 Gutierrez, P., 339

Ha, A., 86
 Hadas-Halpern, I., 837
 Hall, P.M., 242
 Hansen, K.J., 214
 Hara, S., 6:E103
 Harries, S., 933
 Hauser, A.-C., 446
 Hauser, L., 446
 Hayward, R.A., 406
 Heap, M., 1038
 Hedayati, S.S., 642
 Hedicar, S., 5:E91
 Heeringa, P., 253
 Heimbürger, O., 628
 Hemmelgarn, B., 1117
 Hemmi, N., 603
 Herman, J., 58
 Hernandez, D., 339
 Hesse, A., 440
 Higa, Y., 6:E103
 Hirsch, D.J., 509
 Hise, M.K., 997
 Hofman, R.M., 5:E91
 Hogan, S.L., 812
 Holdaas, H., 529
 Holland, D., 799
 Hoppe, B., 440
 Hor, L.-I., 432
 Hörl, W.H., 446, 520
 Hoshino, J., 6:E103
 Houston, T.K., 595
 Hsueh, P.-R., 2:E21
 Huang, J.-J., 432
 Huang, J.-W., 2:E21
 Huisman, R.M., 102
 Humphreys, B.D., 143
 Hurdle, J.F., 537
 Hyton, T.N., 11
 Hyodo, T., 4:E59

Iaccarino, P., 18
 Ikee, R., 603
 Ikenoue, T., 4:E59
 Ikizler, T.A., 976
 Imakiire, T., 603, 4:E59
 Irish, W., 720
 Ishida, H., 688
 Ishii, Y., 688
 Izumi, T., 4:E59

Jaffe, J.A., 316
 Jardine, A.G., 529
 Jassal, S.V., 136
 Jensen, J.D., 470
 Jhangri, G.S., 1117
 Jiménez-Heffernan, J.A., 938
 Jindal, K., 933
 Joffe, M.M., 734
 Joffy, S., 1
 John, R.I., 610
 Johnson, A.M., 415
 Johnson, R.J., 4:E55
 Joukhadar, C., 903
 Juknis, H.I., 94
 Jurkovitz, C., 11
 Kadoguti, K., 6:E103
 Kajbaf, S., 86
 Kalantar-Zadeh, K., 290, 489
 Kanai, H., 688
 Kappel, J., 799
 Karamperis, N., 470
 Kasiske, B.L., 995
 Katori, H., 6:E103
 Kausz, A.T., 871, 887
 Kawai, H., 688
 Kazmi, W.H., 887
 Keiran, S., 3:Ixi, 3:E31
 Kelleher, C.L., 1145
 Kellerman, P.S., 746
 Kelly, G., 111
 Kempson, M.E., 610
 Keough-Ryan, T.M., 845
 Keven, K., 1:E13
 Khouri, N., 1124
 Kiberd, B.A., 845
 Kiefe, C.I., 595
 Kielstein, J.T., 186
 Kikuchi, Y., 603, 4:E59
 Kilpatrick, R.D., 489
 Kimmel, P.L., 577
 King, B.F., 1058
 Kingma, H.A., 102
 Kitahara, T., 688
 Kitajima, I., 6:E103
 Klag, M.J., 78
 Klarenbach, S., 933
 Klassen, P.S., 58
 Klein, R., 214
 Knebelmann, B., 3:E41
 Ko, Y.-H., 432
 Kobayashi, S., 603, 749
 Koçer, B., 1:E13
 Komatsuda, A., 2:E25
 Kopp, C.W., 520
 Kopple, J.D., 489
 Korevaar, J.C., 925
 Kortsaris, A., 706
 Koyanagi, H., 688
 Kramer, R., 424
 Kramer, H., 587
 Kraus, M.A., 4:xlviii, 4:E47, 967
 Krediet, R.T., 925
 Krishnan, M., 481
 Kronenberg, F., 424
 Kshirsagar, A.V., 812
 Kulinskaya, E., 856
 Kumar, J., 573
 Kumar, V.A., 820
 Kumasaka, R., 4:E65
 Kuo, P.-W., 635
 Kurth, T., 871
 Kusano, E., 697
 Kusek, J.W., 455
 Kuypers, D.R.J., 5:E75
 Kwan, B.C.-H., 128
 Kyle, R.A., 278
 Lacy, M.Q., 270
 Lam, C.W.-L., 713
 Lamb, E.J., 610
 Larson, D.R., 278
 Lasagni, L., 550
 Lau, K.K., 1140
 Laube, N., 440
 Law, M.-C., 128
 Lazarus, M., 481
 Lazzeri, E., 550
 Lee, H.-R., 1099
 Lee, T., 501
 Leitão, A.A., 957
 Leite, C.A., 957
 LeMeur, Y., 6:E113
 Lens, X.M., 52
 Lentine, K.L., 720
 Lerut, E., 5:E75
 Leung, C.-B., 128, 713
 Leung, N., 270
 Levey, A.S., 455, 871
 Levin, A., 799
 Levin, R., 1080
 Levitski-Heikkila, T.V., 6:E119
 Levy, J., 173
 Lezotte, D.C., 1049
 Lhotta, K., 424
 Li, L., 720
 Li, P.K.-T., 128, 713
 Li, Y.-J., 6:E125
 Liakopoulos, V., 706
 Libório, A.B., 957
 Lien, Y.H., 58
 Lifftman, C., 316
 Lin, C.-Y., 328
 Lin, J.-L., 6:E125
 Lin, M.-I., 635
 Linas, S.L., 1145
 Lindholm, B., 628
 Lino, M., 3:E41
 Liu, J., 661
 Liu, W., 58
 Liu, Y., 78
 Lo, K.-Y., 5:E87
 Lo, M.-w., 5:E87
 Logan, J.O., 529
 Lopez, V., 1074
 López-Cabrera, M., 938
 Lorenzo, V., 339
 Love, T.E., 621
 Luciani, G., 371
 Luke, A., 587
 Macdougall, I.C., 283
 MacGregor, M.S., 1065
 MacNeily, A.E., 351
 Macron-Nogués, F., 309
 Madsen, S., 529
 Maes, B., 529
 Maesato, K., 749
 Magee, C.C., 143
 Mägner, P., 799
 Mähr, N., 424
 Mak, S.-K., 5:E87
 Mange, K.C., 734
 Manley, H.J., 669
 Manson, J.E., 871
 Markowitz, G.S., 780
 Martin, P.C., 881
 Martini-Filho, D., 4:E51
 Martin-Malo, A., 68
 Masai, R., 2:E25
 Matsell, D., 351
 Matsumoto, H., 697
 Matsumoto, T., 688
 Mayer, G., 424
 Mazzinghi, B., 550
 McAllister, C.J., 489
 McCary, L.C., 58
 McClellan, W.M., 11, 595
 McGee, D., 587
 McLaughlin, J.K., 863
 Mendelssohn, D.C., 1088
 Menon, V., 455
 Mentari, E.K., 621
 Merkin, S.S., 203
 Meyer, K.B., 1107
 Miller, J.P., 1058
 Miller, L.G., 290
 Mimran, A., 233
 Minar, E., 520
 Minutolo, R., 18
 Miskulin, D.C., 557
 Mitchell, R.L., 774
 Miura, S., 603, 4:E59
 Mogun, H., 225
 Momose, A., 4:E65
 Moriya, H., 603, 749
 Morrison, K.B., 351
 Mougenot, B., 1124
 Muirhead, N., 799
 Mukouyama, Y., 697
 Mulhern, J.G., 560
 Munjal, S., 4:E55
 Murray, P.T., 26

Muscaritoli, M., 371
 Muto, S., 697

Nair, R., 362
 Nakamura, M., 4:E65
 Nakamura, N., 4:E65
 Namiki, S., 697
 Nanovic, L., 5:E91
 Nass, C.M., 35
 Nast, C.C., 1146
 Nef, P.C., 242
 Negishi, K., 749
 Nergizoglu, G., 1:E13
 Neumayer, H.-H., 529
 Newsome, B.B., 595
 Neyer, U., 424
 Nissenson, A.R., 301
 Njalsson, R., 1:E5
 Noël, L.-H., 3:E41
 Noguchi, T., 688
 Nojima, Y., 688
 Nomura, K., 6:E103
 Noordzij, M., 925
 Novales, E.L. de, 1074
 Nuñez-Roldan, A., 345
 Nyberg, G., 529
 Nyrén, O., 863

Obialo, C.I., 881
 Obrador, G.T., 650, 887
 O'Connor, A.S., 621, 766
 Ofili, E.O., 881
 Ofman, J.J., 481
 Ofsthun, N.J., 481
 Ohashi, M., 697
 Ohtake, T., 749
 Ohtani, H., 2:E25
 Ojo, A.O., 406
 Oka, M., 749
 Okamoto, K., 749
 Okumura, K., 4:E65
 Okuyama, S., 2:E25
 Olsson, A.G., 529
 O'Neill, W.C., 1058
 Ono, K., 688
 Ooms, V., 5:E75
 O'Reilly, K., 2:lii, 2:E17
 Osawa, H., 4:E65
 O'Shea, M.H., 560
 Outeda, P., 52
 Oyama, N., 4:E65

Pabinger-Fasching, I., 446
 Pannu, N., 933
 Paolletti, E., 320
 Paraf, F., 6:E113
 Parikh, C., 1049, 1129
 Park, J., 791
 Pasquali, S., 120
 Patel, U.D., 406
 Patey, N., 3:E41

Patrick, A.R., 225
 Pedersen, T., 529
 Pelle, G., 1124
 Peng, S.-J., 1099
 Perazella, M.A., 1129
 Pereira, A.A., 455
 Pereira, B.J.G., 887
 Pérez-Lozano, M.L., 938
 Perrone, R.D., 557
 Perry, E., 111
 Person, S.D., 595
 Peters, T.G., 760
 Piazza, M., 464
 Pichette, V., 58, 799
 Pisani, A., 120
 Plevak, M.F., 278
 Poggio, E.D., 242
 Pogliani, D., 897
 Porter, G.A., 988
 Powe, N.R., 203, 1107
 Praxedes, J.N., 957
 Preston, E., 856
 Price, C.P., 610
 Prischl, F., 424
 Procaccini, D., 120
 Puttinger, H., 520

Quarshie, A., 881
 Quehenberger, P., 446
 Qureshi, A.R., 628

Rabb, H., 967
 Rabel-Filho, O.C., 4:E51
 Raman, T., 1:E5
 Ramírez-Huesca, M., 938
 Ramkumar, N., 577
 Ratanjeev, S.K., 3:E35
 Reijngoud, D.-J., 102
 Rerolle, J.-P., 6:E113
 Rexrode, S., 681
 Ribeiro, L.C., 4:E51
 Ribstein, J., 233
 Ricanati, E.S., 621
 Rietschel, E., 440
 Ristoff, E., 1:E5
 Riva, A., 897
 Robbin, M.L., 1058
 Roberts, T.L., 650
 Roche, A., 283
 Rodger, S.C., 949
 Roditi, G., 1065
 Rodriguez, M., 68
 Rodriguez-Benot, A., 68
 Rohr, M., 464
 Rolla, D., 320
 Romagnani, P., 550
 Rondeau, E., 1124
 Rose, C.L., 845
 Rosenberg, M.E., 995
 Rosner, M.H., 1
 Ross, E.A., 908

Rossini, M., 573, 982
 Rothstein, M., 94
 Roux, A.V.D., 203
 Rudensky, B., 837
 Ruilope, L.M., 1074
 Russell, G., 464
 Russell, J., 1038
 Rustin, P., 3:E41
 Rutgers, A., 253

Sabbatini, M., 120
 Said, M., 362
 St. Peter, W.L., 650, 669
 Salanave, B., 309
 Salvadori, M., 550
 Sam, R., 6:lii, 6:E101
 Samuels, J., 26
 Sanchez, E., 339
 Sánchez-Tomero, J.A., 938
 Sarnak, M.J., 455
 Savoldi, S., 120
 Sawa, N., 6:E103
 Sawada, K.-i., 2:E25
 Scandling, J.D., 165, 537
 Schaller, G., 520
 Schaubel, D.E., 136
 Schelling, J.R., 766
 Schneeweiss, S., 225, 1080
 Schnitzler, M.A., 720
 Schrier, R.W., 415
 Schulman, G., 976
 Sebata, K., 697
 Segers, H., 5:E95
 Segura, J., 1074
 Sehgal, A.R., 621
 Seidinger, D., 520
 Seifert, J., 143
 Sekhon, I., 4:E55
 Sekihara, T., 688
 Selgas, R., 938
 Serpaggi, J., 3:E41
 Sethi, S., 159
 Shah, G.N., 5:l, 5:E71
 Shaw, A.D., 26
 Shimada, M., 4:E65
 Shinaberger, C.S., 489
 Shinohara, M., 688
 Shoham, D., 812
 Shoji, F., 697
 Shoker, A., 799
 Siddiqui, S., 1065
 Sidhu, H., 440
 Siegel, D.S., 780
 Signoriello, G., 18
 Silva, M.D., 4:E51
 Simpson, R.J.Jr., 812
 Singer, J., 799
 Sitar, D.S., 681
 Slot, M., 253
 Sloth, E., 470
 Sly, W.S., 5:l, 5:E71

Smith, C., 949
 Smith, D., 111
 Smith, M.W., 78
 Solid, C., 481
 Solomon, D.H., 225
 Soltyk, G., 799
 Spinelli, L., 120
 Stafford, J., 214
 Stechuchak, K.M., 642
 Stefani, F., 897
 Stefanidis, I., 706
 Stegall, M.D., 974
 Steiner, S., 520
 Stella, A., 897
 Stellgaard, F., 102
 Stenvinkel, P., 387, 628
 Stratton, R.J., 387
 Strippoli, G.F.M., 970
 Stuccio-White, N., 481
 Su, S., 635
 Sunder-Plassmann, G., 520
 Suwabe, T., 6:E103
 Suzuki, S., 603, 4:E59
 Swan, S.K., 995
 Swartz, J., 111
 Swartz, R., 111
 Szechzech, L.A., 642
 Szela, J.-C., 6:E113
 Szeto, C.-C., 128, 713

Tagami, T., 6:E103
 Tailor, P., 1:E5
 Takaichi, K., 6:E103
 Takemoto, F., 6:E103
 Takiuchi, A., 4:E51
 Tam, P., 799
 Taub, K., 1088
 Taylor, H. A., 203
 Taylor, M., 415
 Tazza, L., 371
 Tervaert, J.W.C., 253
 Testagrossa, L., 957
 Thein, H., 3:E35
 Thiard, B., 309
 Thompson, C., 799
 Thompson, K.J., 845
 Thompson, P.A., 1058
 Thornberry, J.M., 746
 Tison, M., 415
 Tobe, S., 799
 Toderico, C., 18
 Tolba, Y.A., 1038
 Tonelli, M., 933, 1117
 Tong, G. M.-W., 5:E85

Torres, A., 339
 Torres, V.E., 1058
 Tortorelli, A., 371
 Toyoshima, I., 2:E25
 Tracy, R.P., 78
 Tsai, I.-J., 830
 Tsai, J.J., 820
 Tsao, L., 780
 Tsau, Y.-K., 830
 Tseng, C.-C., 432
 Tsiagi, P., 706
 Tsuchida, A., 688
 Tumlin, J.A., 26

Ubara, Y., 6:E103
 Ullian, M.E., 6:E119
 Unruh, M.L., 1107

Valsecchi, M.G., 897
 van Breda Vriesman, P., 253
 Vandewoude, K., 5:E91
 Vanhille, P., 3:E41
 Vanholder, R., 5:E95
 Van Lente, F., 242
 van Paassen, P., 253
 Vanrenterghem, Y., 512, 5:E75
 Varaut, A., 3:E41
 Vargemezis, V., 706
 Vaseemuddin, M., 4:xlviii, 4:E47, 6:lii, 6:E101
 Veeneman, J.M., 102
 Veinot, J.P., 86
 Verbeke, J.I.M.L., 5:1, 5:E71
 Verbeke, K., 512
 Vergidis, P.I., 1030
 Verhove, J.C., 233
 Vernay, M., 309
 Verrelli, M., 799
 Verstraete, A., 5:E95
 Vickery, S., 610
 Vijayan, A., 791
 Villicana, R., 270
 Vincenzi, A., 897
 von Unruh, G.E., 440
 Vychytal, A., 520

Wadgymar, J.A., 799
 Wakui, H., 2:E25
 Wang, H.-H., 328
 Wang, J.-D., 635
 Wang, M.-C., 432
 Wang, P.-L., 919
 Wang, P.S., 1080
 Wang, X., 242, 455

Warnock, D.G., 595
 Watanabe, H., 697
 Watanabe, S., 2:E25
 Watanabe, Y., 688
 Watnick, S., 919
 Webb, M.C., 610
 Webster, A.C., 774
 Weise, W.J., 962
 Weissman, N.W., 595
 Weng, F.L., 734
 Wennick, J.M.B., 5:1, 5:E71
 Wetzel, L.H., 1058
 Wetzel, J.F.M., 1012
 Wichmann, I., 345
 Wiggins, J., 147
 Wilson, D.B., 214
 Winkelmayr, W.C., 225, 1080
 Wolzt, M., 520
 Wong, A.K.-M., 5:E87
 Wong, P.-N., 5:E87
 Wong, T.Y., 214
 Wong, T.Y.-H., 713
 Wong, Y., 5:E87
 Worcester, E.M., 263
 Wu, J.-J., 432
 Wu, K.-D., 2:E21
 Wyatt, R.J., 1140

Xu, Y., 1124

Yamabe, H., 4:E65
 Yamada, T., 697
 Yamamoto, Y., 697
 Yang, C.-S., 1099
 Yang, C.-W., 6:E125
 Yang, S.-C., 635
 Yeun, J.Y., 820
 Yonekura, T., 697
 Yoshizawa, N., 4:E59
 Youell, T.D., 5:E81
 Young, E.W., 406
 Youssef, G.M., 509
 Yu, C.-C., 6:E125
 Yu, H.-T., 301

Zamboli, P., 18
 Zandi-Nejad, K., 143
 Zelenitsky, S.A., 681
 Zeveloff, S., 780
 Zimmerman, D., 86
 Zimran, A., 837
 Zoccali, C., 186
 Zuidema, S., 933

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (October 2005), Supplement 2 (October 2005), and Supplement 3 (November 2005) are preceded, respectively, by S1:, S2:, and S3:.

Aboriginal people, transplantation waiting list for hemodialysis, 1117–1123

Access to care, medical evaluation completion rates for renal transplantation, 734–745

Acetaminophen, induction of anion gap metabolic acidosis, 143–146

Acetylsalicylic acid, outcomes for acute coronary syndrome with chronic renal insufficiency, 845–855

Acid-base balance, citrate kinetics in long-term hemodialysis, 903–907

Acute coronary syndrome, with chronic renal insufficiency, outcomes for, 845–855

Acute renal failure (ARF)

- critically ill patients, erythropoietin for, 791–798
- with diabetes mellitus and massive proteinuria, 362–366
- erythropoietin therapy during, 791–798, 967–969
- glucose metabolism in, 367–368(c)
- induced by Brazilian variety of propolis, 6:E125
- laboratory-performed vs. nephrologist-performed urinalysis, 820–829
- with malignant hypertension and intestinal ischemia secondary to juxtaglomerular cell tumor, 957–961
- in older patients, 149
- outcome in ICU according to RIFLE, 1038–1048
- randomized controlled trials, Cochrane Renal Group Report on, 774–779
- in renal allograft, 159–162

uncomplicated, hospital resource utilization and, 1049–1057

Acute tubular necrosis (ATN)

- with disseminated histoplasmosis and thrombotic microangiopathy, 159–162
- early, fenoldopam for, 26–34

Adequacy of dialysis

- Medicare reimbursement changes and, 621–627
- prevention of malnutrition in hemodialysis, 371–386

ADPK. *See* Autosomal dominant polycystic kidney disease

Advance directives for long-term dialysis patients, peer mentoring effects on, 111–119

Adverse events, from iron sucrose as 2-minute push in CKD, 283–289

African Americans. *See also* Race; Racial disparity

- family history of ESRD, risk perception of kidney disease and, 11–17
- peer mentoring effect on end-of-life decision making for long-term dialysis patients, 111–119

Age

- of recipient, allocation of deceased donor kidneys and, 949–956
- renal function estimation in subjects with normal serum creatinine, 233–241

Alcohol poisoning, validation of method for predicting required dialysis time for, 509–511

Aldosterone, in oligo-anuric hemodialysis patients, spironolactone effect on, 94–101

Aldosterone receptor antagonists, proteinuria reduction in CKD and, 45–51

ALERT study, renal transplantation cardiovascular disease risk, 529–536

Allograft

- acute renal failure in, 159–162
- graft-versus-host disease after allogeneic stem cell transplantation, 550–556
- intolerance syndrome, incidence/efficacy of percutaneous embolization for, 339–344
- pretransplantation RRT effect on survival, 537–549
- rejection, MPGN-like injury pattern in, 573–576

Alloimmune response, against GSTT1 antigen in renal transplant recipients, 345–350

Aluminum

- elevation frequency in adult dialysis patients, 316–319
- toxicity, in pediatric chronic kidney disease, S1:70–86

Alzheimer disease, in older patients, 153

Amino-terminal proBNP, and B-type natriuretic peptide in CKD, 610–620

Amyloidosis, due to tubulointerstitial nephritis in Sjögren syndrome, 5:E75

Anaritide (atrial natriuretic peptide), in ESRD, 1–10

ANCA. *See* Antineutrophil cytoplasmic antibodies

Anemia

- darbepoetin alfa in renal transplant recipient during pregnancy, 5:E81
- erythropoietin
- for critically ill patients with ARF requiring RRT, 791–798
- prescribing patterns and hemoglobin outcomes in ESRD, 481–488
- to prevent LV hypertrophy in CKD, 799–811
- sensitivity in ESRD, influence of body fat mass and leptin levels on, 628–634

hemoglobin target, debate over, 970–973

IV iron usage trends in dialysis patients, 650–660

outcomes for acute coronary syndrome with chronic renal insufficiency, 845–855

in primary glomerular disease, 424–431

quality of care, Medicare reimbursement changes and, 621–627

Angioplasty, shorter unassisted patency of vascular access in women after, 167(c)

Angiotensin, spironolactone effect on oligo-anuric hemodialysis patients, 94–101

Angiotensin-converting enzyme inhibitors

with aldosterone receptor antagonists for proteinuria reduction in CKD, 45–51
underusage in elderly diabetics, 1080–1087

Angiotensin receptor blockers (ARBs)
with aldosterone receptor antagonists for proteinuria reduction in CKD, 45–51
renoprotective effects of standard *vs.* high doses in hypertensive nondiabetic nephropathies, 1074–1079
underusage in elderly diabetic patients, 1080–1087

Anion gap metabolic acidosis
acetaminophen-induced and 5-oxoprolinuria acquired in hospital, 143–146
recurrent high, secondary to 5-oxoproline, 1:E1

Ankle-brachial blood pressure index, impact on hemodialysis mortality, 688–696

ANP (atrial natriuretic peptide), in ESRD, 1–10

Anticardiolipin antibodies, during immunoabsorption therapy, 446–454

Anticoagulation
citrate kinetics in long-term hemodialysis therapy, 903–907
CVVH with citrate-based replacement fluid, 908–918

Anti-glomerular basement membrane antibodies, with ANCAs in crescentic glomerulonephritis, 253–262

Anti-glomerular basement membrane disease, in diabetic nephropathy, 362–366

Anti-glutathione S-transferase T1 antibodies, in renal transplant recipients, 345–350

Antihypertensives, for CKD-related hypertension, 18–25

Antilipoarabinomannan antibody (anti-LAM), diagnosis of latent tuberculosis in hemodialysis patients, 706–712

Antineutrophil cytoplasmic antibodies (ANCAs)
myeloperoxidase-specific, with anti-GBM antibodies in crescentic glomerulonephritis, 253–262
in systemic vasculitis, 173–185

Antithymocyte globulin, for systemic vasculitis, 173–185

APACHE II, acute renal failure outcome in ICU, 1038–1048

Apolipoprotein, soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099–1106

ARF. *See* Acute renal failure

ARIC (Atherosclerosis Risk in Communities Study), area socioeconomic status and progressive CKD, 203–213

Arteriosclerosis. *See* Atherosclerosis

Arteriovenous access
blood flow evaluation by optodilutional and ultrasound dilution methods, comparison of, 933–937
thrombosis, hyperhomocysteinemia and, 993–994(letter)
usage in adult in-center hemodialysis patients, S2:21–39

Assessment, geriatric, 151

Asymmetric dimethylarginine, as cardiovascular risk factor in ESRD, 186–202

Atherosclerosis
relationship of resistive index in damaged kidneys, 603–609
renal artery disease diagnosed by MRA, outcome prediction for, 1065–1073

Atherosclerosis, impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on HD mortality, 688–696

Atherosclerosis Risk in Communities Study (ARIC), area socioeconomic status and progressive CKD, 203–213

ATN. *See* Acute tubular necrosis

Atrial fibrillation, prevalence and associated factors in long-term hemodialysis patients, 897–902

Atrial natriuretic peptide (ANP; anaritide), in ESRD, 1–10

Autosomal dominant glomerulocystic kidney disease, novel mutation pattern in, 52–57

Autosomal dominant medullary cystic kidney disease type 2 (MCKD2), novel mutation pattern in, 52–57

Autosomal dominant polycystic kidney disease (ADPKD)
family history diagnosis implications for cardiovascular and renal complications, 415–423
hypertension in individuals at risk for, 557–559
pelvic insufficiency fracture and, 6:E101
sonographic assessment of severity and progression, 1058–1064

Azathioprine, for systemic vasculitis maintenance therapy, 173–185

Bacteria. *See also* specific bacteria
multiple rare environmental peritonitis in long-term peritoneal dialysis patient, 6:E119

β -Blockers, outcomes for acute coronary syndrome with chronic renal insufficiency, 845–855

Bicarbonate turnover, in long-term hemodialysis, 102–110

Biliary atresia, reversibility of nephromegaly in, 830–836

Biopsy
of crescentic glomerulonephritis in diabetic nephropathy, 362–366
relationship of resistive index to atherosclerosis in damaged kidneys, 603–609

Blacks. *See* African Americans; Race; Racial disparity

Bladder substitution, urinary tract infections and, 1030–1037

Bleeding risk
citrate-based replacement fluid for CVVH and, 908–918
thrombolytic-associated, delay in time receipt among Medicare patients with kidney disease, 595–602

Blood pressure. *See also* Hypertension
in oligo-anuric hemodialysis patients, spironolactone effect on, 94–101

Blood urea nitrogen, ratio with serum creatinine in estimating GFR in ill hospitalized patients, 242–252

BMI. *See* Body mass index

BNP. *See* B-type natriuretic peptide

Body fat mass, erythropoietin sensitivity in ESRD and, 628–634

Body fluids, composition of, 356–357

Body mass index (BMI)
chronic kidney disease risk and, 871–880
natural history of chronic renal failure and, 863–870
nephrolithiasis and increased blood pressure in females and, 263–269
renal function estimation in subjects with normal serum creatinine and, 233–241

Body weight change, effect on cardiovascular survival of hemodialysis patients, 489–500

Bolus injection of iron sucrose, as 2-minute push in CKD, 283–289

Bone
 formation and modeling, S1:8–9
 mineral accretion, in CKD, S1:10–11

Bone disease
 asymmetric dimethylarginine accumulation and, 186–202
 in pediatric chronic kidney disease
 assessment of, S1:18–22
 clinical manifestations of, S1:9
 treatment of, S1:87–90
 in pediatric kidney transplant recipient, S1:96–98

Bone morphogenic proteins in ESRD valvular calcifications, compared with general population, 86–93

Book reviews
Chronic Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and Rector's The Kidney (Second Edition), 990–991
Diagnostic Atlas of Renal Pathology: A Companion to Brenner and Rector's Kidney (Seventh Edition), 1146–1147
Handbook of Kidney Transplantation (Fourth Edition), 163–164
Hypertension: A Companion to Brenner and Rector's The Kidney (Second Edition), 988–989
Medical Management of Kidney Transplantation, 165–166
Primer on Kidney Disease (Fourth Edition), 1145
 Brachial-ankle pulse wave velocity, hemodialysis mortality and, 688–696

B-type natriuretic peptide (BNP; nesiritide)
 in ESRD, 1–10
 N-terminal pro-B type
 in CKD, 610–620
 prediction of cardiac disease in asymptomatic CKD, 35–44

Calcifications, cardiovascular
 changes after parathyroideectomy, 464–469
 histological comparison with general population, 86–93

Calcineurin inhibitors, thrombotic microangiopathy in patients receiving marginal kidneys, 1124–1128

Calcium
 citrate kinetics in long-term hemodialysis therapy and, 903–907
 in coronary artery in ESRD, changes after parathyroideectomy, 464–469
 coronary artery scores in ESRD, changes after parathyroideectomy, 464–469
 in dialysate, in pediatric chronic kidney disease, S1:64–67
 KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925–932
 metabolism, evaluation in pediatric CKD, S1:12–17
 in pediatric chronic kidney disease, S1:39–47

Calcium-phosphorus product
 chronic kidney disease mortality and, 455–463
 KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925–932
 in pediatric chronic kidney disease, S1:39–47

Calorimetry of energy expenditure, malnutrition in hemodialysis patients and, 102–110

Canada

chronic renal insufficiency outcomes of acute coronary syndrome in, 845–855
 randomized trial of hemoglobin maintenance to prevent LVH in CKD, 799–811

CAPD. *See* Continuous ambulatory peritoneal dialysis

Carbon dioxide expiration, in long-term hemodialysis, 102–110

Cardiovascular calcifications. *See* Calcifications, cardiovascular

Cardiovascular disease
 atrial fibrillation prevalence in long-term hemodialysis, 897–902
 with chronic renal insufficiency, outcomes for, 845–855
 hypokalemia in Chinese peritoneal dialysis patients and, 128–135
 mineral metabolism abnormalities and chronic kidney disease mortality, 455–463
 risk
 β -fibrinogen haplotypes in dialysis patients and, 78–85
 coronary artery intima-media thickness and chronic kidney disease, 856–862
 in ESRD, asymmetric dimethylarginine and, 186–202
 in peritoneal dialysis patients with ESRD, endothelial progenitor cells and, 520–528
 renal transplantation and, 529–536

Cardiovascular Health Study, renal function changes and renal microvascular abnormalities in elderly, 214–224

Cardiovascular mortality
 dialysis access-related infections and, 1149
 effect of morbid obesity and weight change in hemodialysis patients, 489–500
 hypokalemia in Chinese peritoneal dialysis patients and, 128–135

Catheters
 bacteremia in coronary artery bypass graft of dialysis patient, 962–966
 tethered with retained portions in central vein and right atrium on attempted removal, 3:E35
 tunneled, in hemodialysis, 501–508

Charlson Comorbidity Index (CCI), in measuring baseline comorbidity of kidney transplant patients, 136–142

Children. *See also* Pediatric chronic kidney disease
 with biliary atresia, reversibility of nephromegaly in, 830–836
 in-center hemodialysis, clinical performance measures for, S2:47–57
 purpura followed by proteinuria in, 1140–1144

Chinese patients on peritoneal dialysis, hypokalemia in, 128–135

Chlorambucil, for idiopathic membranous nephropathy, 1012–1029

Cholesterol
 reduction
 cardiovascular disease risk, renal transplantation and, 529–536
 with cholestyramine, effect on renal function, 812–819
 outcomes for ACS with chronic renal insufficiency, 845–855
 of soy protein effects on hyperlipidemic hemodialysis patients, 1099–1106

Cholesterol embolism, atherosclerotic renal artery disease diagnosed by MRA, outcome prediction for, 1065–1073

Chronic kidney disease (CKD). *See also* Pediatric chronic kidney disease

- administration of IV iron sucrose as 2-minute push, 283–289
- asymptomatic, NT-proBNP elevation in, 35–44
- atherosclerotic diagnosed by MRA, outcome prediction for, 1065–1073
- benefits of multinutrient support for maintenance dialysis patients, 387–405
- cardiovascular risk, asymmetric dimethylarginine and, 186–202
- coronary artery intima-media thickness and, 856–862
- erythropoietin therapy for LV hypertrophy prevention, 799–811
- hypertension management in primary and tertiary care, 18–25
- inflammation in, metabolic syndrome and, 577–586
- kidney transplantation waiting list for Aboriginal hemodialysis patients, 1117–1123
- manganese-induced Parkinsonism in maintenance hemodialysis patient, 749–753
- mortality, relationship of phosphorus and calcium-phosphorus product in, 455–463
- nondiabetic predialysis patients, left ventricular hypertrophy in, 320–327
- outcomes of acute coronary syndrome in, 845–855
- patient opinions on allocation of deceased donor kidneys for transplantation, 949–956
- predialysis cinacalcet therapy for secondary parathyroidism, 58–67
- prevalence of left ventricular hypertrophy in, 1148–1149(c)
- progression
 - mortality in elderly diabetics and, 406–414
 - socioeconomic status and, 203–213
- retinal microvascular abnormalities in elderly and, 214–224
- spironolactone reduction of proteinuria in, 45–51
- survival extended by predialysis psychoeducational intervention, 1088–1098
- vaccines for adult patients with, 977–1011

Chronic proteinuric renal diseases, telmisartan standard vs. high doses in hypertensive nondiabetic nephropathies, 1074–1079

Chronic renal failure (CRF)

- with abnormal tubular cells in siblings, 982–987
- erythropoietin sensitivity, influence of body fat mass and leptin levels on, 628–634
- erythropoietin therapy and, 967–969
- natural history of, 863–870

Cinacalcet, for secondary parathyroidism in predialysis CKD, 58–67

Cirrhosis, primary biliary with Fanconi syndrome and tubulointerstitial nephritis, 3:E41

Citrate kinetics, in long-term hemodialysis therapy, 903–907

Clinical laboratory-performed urinalysis, compared with nephrologist-performed urinalysis, 820–829

Cochrane Renal Group Report, of randomized controlled trials, 774–779

Cockcroft-Gault equation

- in normal serum creatinine subjects, influence of age and body mass index on, 233–241
- in estimating GFR in ill hospitalized patients, 242–252

Cohort studies, β -fibrinogen haplotypes, cardiovascular disease risk in dialysis patients and, 78–85

Comorbidity

- baseline, in renal transplant recipients, 136–142
- hypokalemia in Chinese peritoneal dialysis patients and, 128–135
- increased mortality associated with early initiation of dialysis and, 887–896
- medication-related problems in hemodialysis patients, 669–680

Compliance, incident hemodialysis and survival, 1107–1116

Congestive heart failure, de novo, after kidney transplantation, 720–723

Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP), sonographic assessment of severity and progression of AKPKD, 1058–1064

Continuing medical education credit, for peer review of manuscripts, 995–996

Continuous ambulatory peritoneal dialysis (CAPD)

- hypokalemia in Chinese patients, 128–135
- peritonitis due to *Salmonella enteritis* in SLE patient, 2:E21
- Vibrio vulnificus* peritonitis after handling seafood, 5:E87

Continuous venovenous hemofiltration (CVVH), with citrate-based replacement fluid, 908–918

Coronary artery bypass graft, mycotic aneurysms in dialysis patient, 962–966

Coronary artery calcium, in ESRD, changes after parathyroidectomy, 464–469

Coronary artery disease prediction, in asymptomatic CKD, 35–44

Coronary artery intima-media thickness, chronic kidney disease and, 856–862

C-reactive protein (CRP)

- cutoff point and clinical applicability, 368–369(c)
- in diabetic peritoneal dialysis patients, rosiglitazone reduction of, 713–719
- erythropoietin sensitivity in ESRD, influence of body fat mass and leptin levels on, 628–634
- inflammation in CKD, metabolic syndrome and, 577–586

Creatinine, serum

- chronic kidney disease progression in elderly diabetics and, 406–414
- in identifying chronic kidney disease from Medicare claims data, 225–232
- ratio with BUN in estimating GFR in ill hospitalized patients, 242–252

Crescentic glomerulonephritis

- coexistence of ANCA and anti-GBM antibodies in, 253–262
- with diabetic nephropathy, 362–366

p-Cresol, renal clearance time for incident peritoneal dialysis patients, 512–519

CRISP (Consortium of Renal Imaging Studies in Polycystic Kidney Disease), sonographic assessment of severity and progression of ADPKD, 1058–1064

CRP. *See* C-reactive protein

Cryptococcosis, intracranial granuloma with skull osteolysis as complication in kidney transplant recipient, 6:E113

C-type natriuretic peptide, in ESRD, 1–10

Cyclophosphamide
for idiopathic membranous nephropathy, 1012–1029
for systemic vasculitis, 173–185

Cycloporine, for systemic vasculitis, 173–185

Cystic fibrosis, absorptive hyperoxaluria leads to increased risk of urolithiasis and nephrocalcinosis in, 440–445

Cytokines, in HCV infection in maintenance hemodialysis, 290–300

Dapsone, renal hypersensitivity vasculitis associated with, 4:E51

Darbepoetin alfa, for post-renal transplantation anemia during pregnancy, 5:E81

Databases, utility of using Medicare claims data in identifying chronic kidney disease, 225–232

Decisional capacity/competence, in older patients, 151

Delirium, in older patients, 152

Dementia
asymmetric dimethylarginine accumulation and, 186–202
in older patients, 153–154

Demographic factors, hospital resource utilization for uncomplicated acute renal failure and, 1049–1057

Deoxyspergualin, for systemic vasculitis, 173–185

Depression
in long-term hemodialysis, hospitalization risk and, 642–649
in older patients, 152–153
validation of depression screening tools in dialysis, 919–924

Diabetes mellitus
family history of ESRD, risk perception of kidney disease and, 11–17
kidney and, nephrology core curriculum, 766–773
with massive proteinuria and acute renal failure, 362–366
predisposition to emphysematous pyelonephritis and, 432–439
rosiglitazone effect on insulin requirements and CRP in PD patients, 713–719
underuse of ACE inhibitors and ARBs in elderly patients, 1080–1087

Diabetic nephropathy
with crescentic glomerulonephritis, 362–366
randomized controlled trials, Cochrane Renal Group Report on, 774–779

Diagnosis
of ADPKD, role of family history and implications for cardiovascular and renal complications, 415–423
of chronic GVHD after allogeneic stem cell transplantation, 550–556
of crescentic glomerulonephritis in diabetic nephropathy, 362–366
hepatitis C virus, discordance in hemodialysis, 992(letter), 993(reply)

of latent tuberculosis in hemodialysis, value of anti-LAM antibody for, 706–712

Dialysate
calcium concentrations, in pediatric chronic kidney disease, S1:64–67
frequency of elevated serum aluminum in adult dialysis patients and, 316–319
IL-12 and IL-18 levels in effluent, peritonitis outcome and, 328–338

Dialysis. *See also* Hemodialysis; Peritoneal dialysis
early initiation, effect of comorbidity on increased mortality of, 887–896
erythropoietin for ARF patients and, 791–798
for ESRD in France in 2003, prevalence of, 309–325
with Fabry disease, effect of enzyme replacement therapy for, 120–127

fenoldopam for early acute tubular necrosis and, 26–34
frequency of elevated serum aluminum in adult patients, 316–319

hospital resource utilization for uncomplicated acute renal failure, 1049–1057

intravenous iron use trends, 650–660

kidney transplantation waiting list for Aboriginal hemodialysis patients, 1117–1123

late referral, socioeconomic implications of, 881–886

natriuretic peptides in, 1–10

randomized controlled trials, Cochrane Renal Group Report on, 774–779

vaccines for adult chronic kidney disease patients, 997–1011

validation of depression screening tools in, 919–924

Dialysis time, validation of method for predicting for methanol and ethylene glycol poisoning, 509–511

Dialyzer reuse, mortality, incident hemodialysis and, 661–668

Direct costs, hospital resource utilization, uncomplicated acute renal failure and, 1049–1057

Diuretics, for chronic kidney disease-related hypertension, 18–25

Donor kidneys
deceased, allocation for transplantation in CKD, 949–956
marginal, thrombotic microangiopathy after sirolimus use, 1124–1128

Doppler ultrasound, relationship of resistive index with arteriosclerosis in damaged kidneys, 603–609

Dosing regimen
adequacy in high-flux hemodialysis, 681–687
V iron sucrose as 2-minute push for CKD patients, 283–289

Echocardiography, atrial fibrillation prevalence in long-term hemodialysis, 897–902

Economic outcomes, of *S. aureus* septicemia in ESRD patients on hemodialysis, 301–308

Elderly patients
with chronic of kidney disease and diabetes, progression and mortality in, 406–414
with diabetes, underuse of ACE inhibitors and angiotensin II receptor blockers in, 1080–1087

geriatrics nephrology core curriculum, 147–158

retinal microvascular abnormalities in, renal function changes and, 214–224

Emphysematous pyelonephritis predisposition, host and bacterial virulence factors in, 432–439

Endocrine alterations, asymmetric dimethylarginine accumulation and, 186–202

End of life care

- decision making for long-term dialysis, peer mentoring effect on, 111–119
- for older patients, 157–158

Endothelial progenitor cells, cardiovascular disease history in peritoneal dialysis patients with ESRD, 520–528

End-stage renal disease (ESRD)

- asymmetric dimethylarginine as cardiovascular risk factor in, 186–202
- β -fibrinogen haplotypes and CVD risk in dialysis patients, 78–85
- cardiovascular disease history in PD patients, endothelial progenitor cells and, 520–528
- changes in cardiovascular calcification after parathyroidectomy, 464–469
- clinical/economic outcomes of *Staphylococcus aureus* septicemia, 301–308
- clinical performance measures project, S2:1–100
- comorbidity effect on increased mortality associated with early initiation of dialysis, 887–896
- depression associated with long-term hemodialysis, hospitalization risk and, 642–649
- end-of-life decision making, peer mentoring effect on, 111–119
- epoetin alfa prescribing patterns and hemoglobin outcomes, 481–488
- erythropoietin sensitivity, influence of body fat mass and leptin levels on, 628–634
- incident hemodialysis, reuse-associated mortality and, 661–668
- mortality risk in hemodiafiltration and, 167–168(c)
- natriuretic peptides in, 1–10
- nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis in, 754–759
- oligo-anuric hemodialysis patients, spironolactone effects on, 94–101
- quality of care, Medicare reimbursement changes and, 621–627
- quality of life in HD patients measured by WHOQOL-BREF(TW), 635–641
- risk perception of, 11–17
- treated with renal dialysis, prevalence in France in 2003, 309–315
- valvular calcifications, histological comparison with general population, 86–93

Energy expenditure, in long-term hemodialysis, 102–110

Enteral nutrition benefits, for CKD maintenance dialysis patients, 387–405

Enzyme HCV immunoassay, low sensitivity in maintenance hemodialysis patients, 290–300

Enzyme replacement therapy for Fabry disease, effect on quality of life and organ involvement, 120–127

Eosinophilia in atherosclerotic renal disease, outcome prediction for, 1065–1073

EPO. *See* Erythropoietin

Epoetin alfa in ESRD, recent prescribing patterns and hemoglobin outcomes, 481–488

Epstein-Barr virus, renal leiomyoma in pediatric transplant patient and, 351–355

Equity of access, allocation of deceased donor kidneys for transplantation, 949–956

Erythropoietin (EPO)

- during acute kidney disease, 967–969
- for critically ill patients with ARF requiring renal replacement therapy, 791–798

in ESRD

- recent prescribing patterns and hemoglobin outcomes, 481–488
- sensitivity influenced by body fat mass and leptin levels, 628–634
- optimal hemoglobin target, debate over, 970–973
- to prevent LV hypertrophy in CKD, 799–811

Escherichia coli gas production, predisposition to emphysematous pyelonephritis and, 432–439

ESRD Clinical Performance Measures Project, 2004 annual report, S2:4–100

Etanercept, for systemic vasculitis, 173–185

Ethylene glycol poisoning, validation of method for predicting required dialysis time for, 509–511

Extramedullary hematopoiesis, in multiple myeloma, 780–786

Fabry disease dialysis patients, effect of enzyme replacement therapy for, 120–127

Falls, in older patients, 154–155

Familial juvenile hyperuricemic nephropathy, novel mutation pattern in, 52–57

Family history of ESRD, race and, 11–17

Fanconi syndrome, and tubulointerstitial nephritis in primary biliary cirrhosis, 3:E41

Females

- allocation of deceased donor kidneys for transplantation, 949–956
- natural history of chronic renal failure and, 863–870
- nephrolithiasis and increased blood pressure with high BMI, 263–269
- proteinuria and Hgb levels in primary glomerular disease, 424–431
- shorter unassisted patency of vascular access after angioplasty, 167(c)

Fenoldopam mesylate, for early acute tubular necrosis, 26–34

Ferric gluconate, intravenous usage trends in dialysis patients, 650–660

Fetal loss, anticardiolipin antibodies during immunoadsorption therapy and, 446–454

β -Fibrinogen haplotypes, risk of cardiovascular disease in dialysis cohort and, 78–85

Fibrosis, with nephrogenic fibrosing dermopathy, 754–759

Fistula, tunneled catheters in hemodialysis patients, 501–508

Focal and segmental glomerulosclerosis, plasma cell disorders and, 278–282

Frailty, of older patients, 156

France, prevalence of ESRD treated with renal dialysis in 2003, 309–315

α -Galactosidase A for Fabry disease, effect on quality of life and organ involvement, 120–127

Gaucher disease, comprehensive renal function assessment in, 837–844

Gender. *See* Females; Males

Genius® Batch Hemodialysis System, efficiency with low serum solute concentrations, 5:E95

Genotype mismatch, alloimmune response against GSTT1 in renal transplant recipients, 345–350

Geriatrics, nephrology core curriculum, 147–158

GFR. *See* Glomerular filtration rate

Glomerular disease, in older patients, 149–150

Glomerular filtration rate (GFR)

- estimation
 - in ill hospitalized patients, 242–252
 - in subjects with normal creatinine levels, effect of age and BMI on, 233–241
- in identifying chronic kidney disease from Medicare claims data, 225–232

Glomerular hyperfiltration in Gaucher disease, renal function and, 837–844

Glomerular tip lesions, nonsteroidal anti-inflammatory drug-induced nephrotic syndrome and, 4:E55

Glomerulitis, acute transplant, MPGN-like injury pattern in, 573–576

Glomerulonephritis

- crescentic
 - coexistence of ANCA and anti-GBM antibodies in, 253–262
 - with diabetic nephropathy, 362–366
- hepatitis C virus-associated without hepatitis C virus in blood, 4:E65
- poststreptococcal, complicated by hemolytic uremic syndrome and nephrotic syndrome, 4:E59
- proteinuria and hemoglobin levels in, 424–431

Glucose metabolism, in early renal failure, 367–368(c)

Glutathione, depletion of liver stores in acetaminophen-induced anion gap acidosis, 143–146

Graft. *See* Allograft

Graft intolerance syndrome, incidence/efficacy of percutaneous embolization for, 339–344

Graft-versus-host disease, after allogeneic stem cell transplantation, 550–556

Granuloma, with skull osteolysis in kidney recipient with cutaneous cryptococcosis, 6:E113

Growth hormone therapy

- for pediatric chronic kidney disease, S1:68–69
- renal leiomyoma associated with Epstein-Barr virus in pediatric transplant patient, 351–355

Growth retardation and skeletal maturation delay, in children with CKD, S1:9–10

Haplotypes, β -fibrinogen, risk of cardiovascular disease in dialysis cohort, 78–85

HD. *See* Hemodialysis

Health care disparity, cultural approach for end-of-life planning for long-term dialysis patients and, 111–119

Health-related quality of life, Medicare reimbursement changes and, 621–627

Healthy subjects, effect of oral glucose tolerance test on potassium uptake in, 697–705

Hematocrit, IV iron usage trends in dialysis patients, 650–660

Hematuria, sudden late onset in previous renal transplant recipient after transplant nephrectomy, 5:E91

Hemodiafiltration

- mortality risk in ESRD and, 167–168(c)
- vs. hemodialysis and hemofiltration, 787–789(c)

Hemodialysis (HD). *See also* Maintenance hemodialysis

- access blood flow, optodilutional vs. ultrasound dilution methods, 933–937
- allocation of deceased donor kidneys for transplantation, 949–956
- changes in cardiovascular calcification after parathyroidectomy in ESRD, 464–469
- compared with hemofiltration and hemodiafiltration, 787–789(c)
- effect of oral glucose tolerance test on potassium uptake in, 697–705

for ESRD

- nephrogenic fibrosis/dermopathy/nephrogenic systemic fibrosis in, 754–759
- valvular calcifications, histological comparison with general population, 86–93

Genius® Batch Hemodialysis System efficiency with low serum solute concentrations, 5:E95

high-flux, adequacy of vancomycin dosing regimen in, 681–687

incident, reuse-associated mortality and, 661–668

KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925–932

long-term

- atrial fibrillation prevalence and associated factors in, 897–902
- citrate kinetics in, 903–907
- hospitalization risk, depression and, 642–649
- oxidative metabolism reduction in, 102–110

malnutrition, prevention of, 371–386

medication-related problems, 669–680

morbid obesity and weight change over time effect on cardiovascular survival, 489–500

mortality

- brachial-ankle pulse wave velocity, ankle-brachial blood pressure index and, 688–696
- mild hyperphosphatemia and, 68–77
- mycotic aneurysm in coronary artery bypass graft of dialysis patient, 962–966
- oligo-anuric patients, spironolactone effect on BP and RAAS in, 94–101

pretransplantation, effect on allograft and recipient survival, 537–549

quality of life measured by WHOQOL-BREF(TW), 635–641

skipped treatments, markers of nutritional nonadherence and survival in, 1107–1116

soy protein effect on hyperlipidemic and normolipidemic patients, 1099–1106

techniques and prescription nephrology core curriculum, 976–981

tunneled catheters in, 501–508

Hemodialysis catheters. *See* Catheters

Hemofiltration

mortality risk calculations, 787(c)
risk of mortality in ESRD and, 167–168(c)
vs. hemodialysis and hemodiafiltration, 787–789(c)

Hemoglobin
 A_{1C} predisposition to emphysematous pyelonephritis and, 432–439
epoetin alfa prescribing patterns in ESRD and, 481–488
optimal target, debate over, 970–973
in primary glomerular disease, 424–431

Hemolytic uremic syndrome, with nephrotic syndrome and poststreptococcal glomerulonephritis, 4:E59

Henoch-Schönlein purpura, followed by proteinuria in child, 1140–1144

Hepatitis C virus
alloimmune response against GSTT1 in renal transplant recipients, 345–350
diagnostic discordance in hemodialysis, 992(letter), 993(reply)
glomerulonephritis, without hepatitis C virus in blood, 4:E65
identification in maintenance hemodialysis patients, 290–300
Hepatoblastoma, reversibility of nephromegaly in biliary atresia, 830–836

Hepatocyte growth factor, degree of nephromegaly in biliary atresia, 830–836

High-flux membranes, adequacy of vancomycin dosing regimen in hemodialysis, 681–687

Histoplasmosis, with thrombotic microangiopathy and acute tubular necrosis, 159–162

HLA haplotype, chronic renal failure with abnormal tubular cells in siblings, 982–987

HLA mismatch, allocation of deceased donor kidneys for transplantation, 949–956

Homocysteine, arteriovenous fistula patency and, 993–994(letter)

Hospitalization, depression and long-term hemodialysis, 642–649

Hospital resource utilization, uncomplicated acute renal failure and, 1049–1057

Human T-cell lymphotropic virus type 1-associated myopathy, and nephritis development in SLE patient, 2:E21

Hypercholesterolemia, cholestyramine effect on renal function, 812–819

Hyperhomocystinemia, arteriovenous fistula thrombosis and, 993–994(letter)

Hypernatremia
etiology and treatment of, 360–361
evaluation, water deprivation test not indicated for, 1150(c)

Hyperoxaluria, increased risk of urolithiasis and nephrocalcinosis in cystic fibrosis and, 440–445

Hyperphosphatemia, mortality in hemodialysis patients and, 68–77

Hypersensitivity vasculitis, associated with dapsone, 4:E51

Hypertension
asymmetric dimethylarginine accumulation and, 186–202
early diagnosis of ADPKD using family history analysis and, 415–423

family history of ESRD, risk perception of kidney disease and, 11–17

in individuals at risk for autosomal dominant polycystic kidney disease, 557–559

left ventricular hypertrophy in nondiabetic CKD patients, 320–327

malignant with intestinal ischemia secondary to juxtaglomerular cell tumor, 957–961

management in primary and tertiary care, 18–25

and nephrolithiasis in females with high BMI, 263–269

with obesity, chronic kidney disease risk and, 587–594

in oligo-anuric hemodialysis patients, spironolactone effect on, 94–101

Hypervolemia, etiology and treatment, 358–359

Hypocitraturia, urolithiasis and nephrocalcinosis risk in cystic fibrosis and, 440–445

Hypokalemia, in Chinese peritoneal dialysis patients, 128–135

Hyponatremia, etiology and treatment of, 359–360

Hypovolemia, etiology and treatment, 358

Idiopathic membranous nephropathy treatment strategy, rationale and outline of, 1012–1029

Immunization, for adult patients with renal disease, 997–1011

Immunoabsorption therapy, anticardiolipin antibodies during, 446–454

Immunosuppression
for idiopathic membranous nephropathy, 1012–1029
renal leiomyoma associated with Epstein-Barr virus in pediatric transplant patient, 351–355
for systemic vasculitis, 173–185

Infection
complications of *S. aureus* in ESRD patients on hemodialysis, 301–308
dialysis access-related, cardiovascular mortality and, 1149
mycotic aneurysms in coronary artery bypass graft of dialysis patient, 962–966
tunneled catheters in hemodialysis patients, 501–508

Inflammation
effect of morbid obesity and weight change on cardiovascular survival of hemodialysis patients, 489–500
erythropoietin sensitivity in ESRD, influence of body fat mass and leptin levels on, 628–634

in ESRD valvular calcifications, compared with general population, 86–93

fibrinogen level elevations in ESRD diabetics, 78–85

Inflammatory markers in diabetic peritoneal dialysis patients, rosiglitazone reduction of, 713–719

Infliximab, for systemic vasculitis, 173–185

Insulin
endogenous, effect on potassium uptake in hemodialysis vs. healthy patients, 697–705
requirement of diabetic peritoneal dialysis patients, rosiglitazone reduction of, 713–719

Intensive care unit, acute renal failure outcome according to RIFLE, 1038–1048

Interferon γ , expression in peritoneal T-cells in PD-related peritonitis, 328–338

Interleukin 12, in peritoneal dialysate effluent, peritonitis outcome and, 328–338

Interleukin 18, in peritoneal dialysate effluent, peritonitis outcome and, 328–338

Intestinal conduit urinary diversion, urinary tract infections and, 1030–1037

Intestinal pouch, urinary tract infections and, 1030–1037

Intracranial granuloma, with skull osteolysis as complication of cutaneous cryptococcosis in kidney transplant recipient, 6:E113

Iodine 125-iothalamate clearances, in estimating GFR in ill hospitalized patients, 242–252

Iron, intravenous as 2-minute push to CKD patients, 283–289 usage trends in dialysis patients, 650–660

Iron deficiency, IV iron sucrose as 2-minute push for CKD patients, 283–289

Juxtaglomerular cell tumor, secondary intestinal ischemia with malignant hypertension, 957–961

Karyomegaly, chronic renal failure with abnormal tubular cells in siblings, 982–987

KDOQI. *See* Kidney Disease Outcomes Quality Initiative

KEEP (Kidney Early Evaluation Program), annual data report 2005, S3:1–158

Kidney allocation policy, development of, 974–975

Kidney Disease Outcomes Quality Initiative (KDOQI) epoetin alfa prescribing patterns and hemoglobin outcomes in ESRD, 481–488

guidelines for bone metabolism and disease in CKD, 925–932

Kidney disease severity, delay in time receipt of thrombolytic medication, 595–602

Kidney Early Evaluation Program (KEEP), annual data report 2005, S3:1–158

Kidney function B-type natriuretic peptide and amino-terminal proBNP in CKD and, 610–620 changes, retinal microvascular abnormalities in elderly and, 214–224 comprehensive assessment in Gaucher disease, 837–844 effect of cholesterol reduction with cholestyramine on, 812–819 estimation in subjects with normal serum creatinine levels, effect of age and BMI on, 233–241 impairment, recognizing in older patients, 147

Kidney transplant recipients allocation of deceased donor kidneys and, 949–956 alloimmune response against GSTT1 antigen in, 345–350 baseline comorbidity in, 136–142 darbepoetin alfa for anemia during pregnancy, 5:E81 intracranial granuloma with skull osteolysis as complication of cutaneous cryptococcosis in, 6:E113 older, 150–151 pediatric, bone disease in, S1:96–98 pretransplantation RRT effect on survival, 537–549 prognosis, baseline comorbidity in, 136–142 sudden late gross hematuria after transplant nephrectomy, 5:E91

Kidney volume, sonographic assessment of severity and progression of AKPKD, 1058–1064

Latent tuberculosis, value of anti-LAM antibody in diagnosis in hemodialysis patients, 706–712

Leflunomide, for systemic vasculitis, 173–185

Left ventricular hypertrophy (LVH) B-type natriuretic peptide and amino-terminal proBNP in CKD and, 610–620 erythropoietin therapy for prevention in CKD, 799–811 in Fabry disease dialysis patients, effect of enzyme replacement therapy on, 120–127 in nondiabetic predialysis CKD, 320–327 prediction, in asymptomatic CKD, 35–44 prevalence in CKD, 1148(c)

Length of stay *Staphylococcus aureus* septicemia in ESRD hemodialysis patients, 301–308 uncomplicated acute renal failure and, 1049–1057

Leptin, erythropoietin sensitivity in ESRD and, 628–634

Leukemia, pseudohyperkalemia due to pneumatic tube transport, 746–748

Lipids reduction cardiovascular disease risk, renal transplantation and, 529–536 with cholestyramine, effect on renal function, 812–819 outcomes for ACS with chronic renal insufficiency, 845–855 soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099–1106

Lipoprotein, soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099–1106

Lithium intoxication therapy, efficiency of Genius® Batch Hemodialysis System for, 5:E95

Liver transplantation, reversibility of nephromegaly in biliary atresia, 830–836

LVH. *See* Left ventricular hypertrophy

Lysosomal storage disease, comprehensive renal function assessment in, 837–844

Magnetic resonance angiography, atherosclerotic renal artery disease outcome prediction, 1065–1073

Magnetic resonance imaging, of AKPKD severity and progression, 1058–1064

Maintenance hemodialysis benefits of enteral nutritional support for CKD, 387–405 identification of HCV in, 290–300 manganese-induced Parkinsonism and, 749–753

Males allocation of deceased donor kidneys for transplantation, 949–956 family history of ESRD, risk perception of kidney disease and, 11–17 natural history of chronic renal failure and, 863–870 proteinuria and Hgb levels in primary glomerular disease, 424–431

Malnutrition effect of weight change on cardiovascular survival of hemodialysis patients, 489–500 in hemodialysis patients, 371–386

Malnutrition-inflammation-cachexia syndrome, in HCV infection in maintenance hemodialysis, 290-300

Manganese, induction of Parkinsonism in maintenance hemodialysis patient, 749-753

MCKD2 (autosomal dominant medullary cystic kidney disease type 2), novel mutation pattern in, 52-57

MDRD equation. *See* Modification of Diet in Renal Disease equation

Medical evaluation, completion rates for renal transplantation, 734-745

Medicare claims data

- de novo congestive heart failure after kidney transplantation, 720-723
- identifying chronic kidney disease from, 225-232
- reimbursement changes, 621-627

Medication-related problems, in hemodialysis patients, 669-680

Melphalan, renal response in primary systemic amyloidosis and, 270-277

Membranoproliferative glomerulonephritis, injury pattern in renal allograft, 573-576

Mesothelial cells, mesenchymal conversion, high solute transport rate in peritoneal dialysis and, 938-948

Meta-analysis, benefits of multinutrient support for CKD maintenance dialysis patients, 387-405

Metabolic acidosis

- acetaminophen-induced and 5-oxoprolinuria acquired in hospital, 143-146
- in pediatric chronic kidney disease, S1:94-95

Metabolic syndrome, associations with inflammation in CKD, 577-586

Methanol poisoning, validation of method for predicting required dialysis time for, 509-511

Methotrexate, for systemic vasculitis, 173-185

Methylenetetrahydrofolate reductase genotype polymorphism (MTHFR), arteriovenous fistula patency and, 993-994(letter)

Methylprednisolone, for systemic vasculitis, 173-185

MGUS (monoclonal gammopathy of undetermined significance), focal and segmental glomerulosclerosis and, 278-282

Microvasculature retinal abnormalities in elderly, renal function changes and, 214-224

Mineral metabolism abnormalities, chronic kidney disease mortality and, 455-463

Minimal change disease

- after allogeneic stem cell transplantation, 550-556
- with stiff-person syndrome, 1:E13

Modification of Diet in Renal Disease equation (MDRD) in estimating GFR in ill hospitalized patients, 242-252

influence of age and body mass index on normal serum creatinine level subjects, 233-241

Monoclonal antibodies, for systemic vasculitis, 173-185

Monoclonal gammopathy of undetermined significance (MGUS), focal and segmental glomerulosclerosis and, 278-282

Monoclonal light chain fragments in primary systemic amyloidosis, renal response after stem cell transplantation and, 270-277

Morbidity, vaccines for adult chronic kidney disease patients, 997-1011

Mortality

- all-cause risk in incident dialysis, KDOQI control guidelines and, 925-932
- chronic kidney disease, relationship of phosphorus and calcium-phosphorus product in, 455-463
- chronic of kidney disease, in elderly diabetics, 406-414
- early initiation of dialysis, effect of comorbidity on, 887-896
- fenoldopam for early acute tubular necrosis and, 26-34
- impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on, 688-696
- mild hyperphosphatemia in hemodialysis patients and, 68-77
- pretransplantation renal replacement therapy effect on, 537-549
- rates

 - depression and long-term hemodialysis, 642-649
 - natural history of chronic renal failure and, 863-870
 - reuse-associated mortality, incident hemodialysis and, 661-668

- risk

 - calculations, for hemofiltration, 787(c)
 - end-stage renal disease hemodiafiltration and, 167-168(c)

- uncomplicated acute renal failure and, 1049-1057
- vaccines for adult chronic kidney disease patients, 997-1011

MPO-ANCA (myeloperoxidase-specific antineutrophil cytoplasmic antibodies), with anti-GBM antibodies in crescentic glomerulonephritis, 253-262

MTHFR (methylenetetrahydrofolate reductase genotype polymorphism), arteriovenous fistula patency and, 993-994(letter)

Multidisciplinary predialysis care, effect on survival in CKD, 1088-1098

Multiple myeloma

- extramedullary hematopoiesis in, 780-786
- focal and segmental glomerulosclerosis and, 278-282

Musculoskeletal deformities, in children with CKD, S1:10

Mycophenolate mofetil, for systemic vasculitis, 173-185

Mycotic aneurysm, in coronary artery bypass graft of dialysis patient, 962-966

Myeloma cast nephropathy, case report, 780-786

Myeloperoxidase-specific antineutrophil cytoplasmic antibodies (MPO-ANCA), with anti-GBM antibodies in crescentic glomerulonephritis, 253-262

National Health and Nutrition Examination Survey (NHANES III), associations of metabolic syndrome with inflammation in CKD, 577-586

National Kidney Foundation. KEEP annual data report 2005, S3:1-158

Natriuretic peptides

- in CKD, relationship to renal function and left ventricular hypertrophy, 610-620
- in ESRD, 1-10
- prediction of cardiac disease in asymptomatic CKD, 35-44

Neobladder, urinary tract infections and, 1030-1037

Nephritis development in SLE patient, with human T-cell lymphotropic virus type 1-associated myopathy, 2:E21

Nephrocalcinosis risk in cystic fibrosis, absorptive hyperoxaluria and, 440–445

Nephrogenic fibrosing dermopathy
nephrogenic systemic fibrosis and, 763–765
with systemic fibrosis, 754–759

Nephrogenic systemic fibrosis, evolution of nephrogenic fibrosing dermopathy and, 763–765

Nephrolithiasis, and increased blood pressure in females with high BMI, 263–269

Nephrologist-preformed urinalysis, vs. clinical laboratory performed urinalysis, 820–829

Nephrology clinic, hypertension management in, 18–25

Nephrology core curriculum
diabetes and the kidney, 766–773
disorders of sodium and water, 356–361
geriatrics, 147–158
hemodialysis: techniques and prescription, 976–981
pharmacology, 1129–1139
tubulointerstitial diseases, 560–572

Nephromegaly, reversibility in biliary atresia, 830–836

Nephropathy
chronic renal failure with abnormal tubular cells in siblings, 982–987
underusage of ACE inhibitors and ARBs in elderly diabetics, 1080–1087

Nephroprotection of telmisartan, standard vs. high doses in hypertensive nondiabetic nephropathies, 1074–1079

Nephrotic syndrome
minimal change. *See* Minimal change disease
nonsteroidal anti-inflammatory drug-induced associated with glomerular tip lesion, 4:E55
with poststreptococcal glomerulonephritis and hemolytic uremic syndrome, 4:E59
proteinuria and anemia in, 424–431
and renal failure after allogeneic stem cell transplantation, 550–556
treatment strategy for idiopathic membranous nephropathy, 1012–1029

Nesiritide. *See* B-type natriuretic peptide

NHANES III (National Health and Nutrition Examination Survey III), associations of metabolic syndrome with inflammation in CKD, 577–586

Nitric oxide impaired synthesis from ADMA accumulation, cardiovascular risk in ESRD, 186–202

Nonorthotopic urinary diversion, urinary tract infections and, 1030–1037

Nonsteroidal anti-inflammatory drug-induced nephrotic syndrome, associated with glomerular tip lesion, 4:E55

Nutrition
benefits of nutritional support for CKD maintenance dialysis patients, 387–405
hypokalemia in Chinese peritoneal dialysis patients and, 128–135
nonadherence and survival in incident hemodialysis patients, 1107–1116
for older patients, 157

Obesity
cardiovascular survival of hemodialysis patients and, 489–500
chronic kidney disease risk and, 871–880
with hypertension, chronic kidney disease risk and, 587–594
nephrolithiasis and increased blood pressure in females, 263–269
renal function estimation in subjects with normal serum creatinine and, 233–241

Ochratoxin, CRF with abnormal tubular cells in siblings, 982–987

Oral glucose tolerance test, serum potassium in hemodialysis patients and, 697–705

Oral supplementation
benefits CKD maintenance dialysis patients, 387–405
manganese-induced Parkinsonism in maintenance hemodialysis patient, 749–753

Organ involvement, enzyme replacement therapy for Fabry disease and, 120–127

Osteodystrophy, in pediatric chronic kidney disease
assessment of, S1:18–22
surgical management of, S1:23–25

Osteopontin, in ESRD valvular calcifications, compared with general population, 86–93

Osteoporosis, in older patients, 155

Outcome
baseline comorbidity in renal transplant recipients, 136–142
economic, of *S. aureus* septicemia in ESRD patients on hemodialysis, 301–308
identifying chronic kidney disease from Medicare claims data, 225–232
prediction, in atherosclerotic renal artery disease diagnosed by MRA, 1065–1073

Overweight, chronic kidney disease risk and, 871–880

Oxalobacter formigenes, absorptive hyperoxaluria effect on urolithiasis and nephrocalcinosis risk in cystic fibrosis, 440–445

Oxidative metabolism, reduction in long-term hemodialysis, 102–110

5-Oxoproline, secondary recurrent high anion gap metabolic acidosis, 1:E1

5-Oxoprolinuria, with acetaminophen-induced anion gap metabolic acidosis, 143–146

Parathyroideism, cinacalcet therapy in predialysis CKD and, 58–67

Parathyroidectomy
changes in cardiovascular calcification in ESRD, 464–469
in pediatric chronic kidney disease, S1:91–93

Parathyroid hormone, all-cause mortality risk in incident dialysis and, 925–932

Parkinsonism, manganese-induced in maintenance hemodialysis patient, 749–753

Patient education, predialysis psychoeducational intervention effect on survival in CKD, 1088–1098

Patient-nephrologist visits, Medicare reimbursement changes and, 621–627

Patient opinions, on allocation of deceased donor kidneys for transplantation, 949–956

PD. *See* Peritoneal dialysis
Peak bone mass, in CKD, S1:10–11
Pediatric chronic kidney disease
active vitamin D therapy in, S1:53–63
aluminum overload and toxicity in, S1:70–78
aluminum toxicity treatment in, S1:79–86
bone disease assessment in, S1:18–22
calcium-phosphorus product in, S1:39–47
dietary phosphorus intake in, S1:29–31
evaluation of calcium and phosphorus metabolism in, S1:12–17
growth hormone therapy in, S1:68–69
kidney transplant recipients, bone disease in, S1:96–98
metabolic acidosis in, S1:94–95
parathyroidectomy in, S1:91–93
phosphorus dietary intake in, S1:29–31
prevention and treatment of vitamin D insufficiency and deficiency in, S1:48–52
renal osteodystrophy, surgical management of, S1:23–25
serum calcium levels in, S1:39–47
target serum phosphorus levels in, S1:26–28
treatment of bone disease in, S1:87–90
use of phosphate binders in, S1:32–38
Peer mentoring, effect on end-of-life decision making for long-term dialysis patients, 111–119
Pelvic insufficiency fracture, autosomal dominant polycystic kidney disease and, 6:E101
Peritoneal dialysis (PD)
adult, clinical performance measures for, S2:39–47
changes in cardiovascular calcification after parathyroidectomy in ESRD, 464–469
endothelial progenitor cells and cardiovascular disease history in ESRD, 520–528
high solute transport rate in, mesenchymal conversion of mesothelial cells and, 938–948
hypokalemia in Chinese patients, 128–135
KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925–932
long-term, multiple rare environmental bacteria peritonitis in, 6:E119
natriuretic peptides in, 1–10
peritonitis, T-cell immune response in, 328–338
pretransplantation, effect on allograft and recipient survival, 537–549
rosiglitazone reduction of insulin requirements and CRP in diabetic patients, 713–719
time profiles of renal clearances for uremic solutes in, 512–519
Peritoneal transport rate, mesenchymal conversion of mesothelial cells in peritoneal dialysis and, 938–948
Peritonitis
CAPD-related, due to *Salmonella enteritidis* in SLE patient, 2:E21
with multiple rare environmental bacteria in long-term peritoneal dialysis patient, 6:E119
peritoneal-dialysis related, T-cell immune response in, 328–338
from *Vibrio vulnificus* after handling seafood in patient receiving CAPD, 5:E87
Pharmacokinetics, in older patients, 148–149
Pharmacology
medication-related problems in hemodialysis patients, 669–680
nephrology core curriculum, 1129–1139
Phosphate binders
frequency of elevated serum aluminum in adult dialysis patients, 316–319
use in pediatric chronic kidney disease, S1:32–38
Phosphate serum levels, mortality in hemodialysis patients and, 68–77
Phosphorus
chronic kidney disease mortality and, 455–463
dietary intake in pediatric chronic kidney disease, S1:29–31
KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925–932
metabolism, evaluation in pediatric CKD, S1:12–17
Plasma cell disorders, focal segmental glomerulosclerosis and, 278–282
Plasma exchange, for systemic vasculitis, 173–185
Pneumatic tube transport, pseudohyperkalemia in leukemic patient, 746–748
Population-modeling program, vancomycin dosing regimen adequacy in high-flux hemodialysis, 681–687
Postinfectious glomerulonephritis
complicated by hemolytic uremic syndrome and nephrotic syndrome, 4:E59
purpura followed by proteinuria in child, 1140–1144
Potassium, serum
in Chinese peritoneal dialysis patients, 128–135
effect of oral glucose tolerance test hemodialysis patients and, 697–705
spironolactone effect on oligo-anuric hemodialysis patients and, 94–101
spironolactone reduction of proteinuria in CKD and, 45–51
Predialysis patients with CKD, cinacalcet therapy for secondary parathyroidism, 58–67
Predictive value, of identifying chronic kidney disease from Medicare claims data, 225–232
Preemptive transplantation, medical evaluation completion rates for renal transplantation, 734–745
Pregnancy, darboepoetin alfa for anemia in renal transplant recipient, 5:E81
Primary care management, of hypertension, 18–25
Primary systemic amyloidosis, renal response after high-dose melphalan and stem cell transplantation, 270–277
Prognosis
for atherosclerotic renal disease diagnosed by MRA, 1065–1073
baseline comorbidity in renal transplant recipients, 136–142
for chronic renal failure, 863–870
de novo congestive heart failure after kidney transplantation, 720–723
in ESRD, natriuretic peptides and, 1–10
significance of renal response after high-dose melphalan with STM in primary systemic amyloidosis and, 270–277
Prognostic markers, for systemic vasculitis, 173–185
Progression of kidney disease

in elderly diabetics, 406–414
 preventing in older patients, 147–148
 retinal microvascular abnormalities in elderly and, 214–224
 telmisartan standard *vs.* high doses in hypertensive non-diabetic nephropathies, 1074–1079
 Proinflammatory cytokines, in HCV infection in maintenance hemodialysis, 290–300
 Propolis, induction of acute renal failure, 6:E125
 Protein-bound solutes, renal clearance time for incident peritoneal dialysis patients, 512–519
Proteinuria
 chronic renal failure with abnormal tubular cells in siblings, 982–987
 early diagnosis of ADPKD using family history analysis and, 415–423
 in FSGS, plasma cell disorders and, 278–282
 in primary glomerular disease, 424–431
 reduction after high-dose melphalan with stem cell transplantation in AL amyloidosis, 270–277
 spironolactone reduction of, in CKD, 45–51
 telmisartan standard *vs.* high doses in hypertensive non-diabetic nephropathies, 1074–1079
Pseudohyperkalemia, due to pneumatic tube transport in leukemic patient, 746–748
Psychoeducational predialysis intervention, effect on survival in CKD, 1088–1098
Purpura, followed by proteinuria in child, 1140–1144
Pyelonephritis, emphysematous, host and bacterial virulence factors in predisposition of, 432–439
Pyroglutamic acid, secondary recurrent high anion gap metabolic acidosis, 1:E1
Pyroglutamic aciduria, acetaminophen-induced anion gap acidosis and, 143–146

Quality of care
 Medicare reimbursement changes and, 621–627
 underusage of ACE inhibitors and ARBs in elderly diabetics, 1080–1087
Quality of life
 enzyme replacement therapy for Fabry disease and, 120–127
 in hemodialysis patients measured by WHOQOL-BREF(TW), 635–641
 peer mentoring effect on end-of-life decision making for long-term dialysis patients, 111–119
 skipped treatments and survival in incident hemodialysis patients, 1107–1116

Race
 family history of ESRD, risk perception of kidney disease and, 11–17
 peer mentoring effect on end-of-life decision making for long-term dialysis patients, 111–119
 skipped treatment, nutritional nonadherence and survival in incident hemodialysis patients, 1107–1116

Racial disparity
 medical evaluation completion rates for renal transplantation, 734–745
 transplantation and, 760–762

Randomized controlled trials

Cochrane Renal Group Report, 774–779
 effect of cholesterol reduction with cholestyramine on renal function, 812–819
 erythropoietin therapy for prevention of left ventricular hypertrophy in CKD, 799–811
Real-time polymerase chain reaction, in diagnosing chronic GVHD after allogeneic stem cell transplantation, 550–556
Referral for dialysis
 early, predialysis psychoeducational intervention effect on survival in CKD, 1088–1098
 late, socioeconomic implications of, 881–886
Rehabilitation, for older patients, 155–156
Relative risk for mortality, mild hyperphosphatemia in hemodialysis and, 68–77
Renal artery atherosclerosis, diagnosed by MRA, outcome prediction for, 1065–1073
Renal clearance time, of uremic solutes for incident peritoneal dialysis patients, 512–519
Renal hypersensitivity vasculitis, dapsone-associated, 4:E51
Renal insufficiency, antidiolipin antibodies during immunoadsorption therapy and, 446–454
Renal leiomyoma, associated with Epstein-Barr virus in pediatric transplant patient, 351–355
Renal replacement therapy (RRT). *See also* Hemodialysis; Peritoneal dialysis
 for acute renal failure, erythropoietin and, 791–798
 for ESRD in France in 2003, prevalence of, 309–325
 late referral, socioeconomic implications of, 881–886
 natural history of chronic renal failure and, 863–870
 predialysis psychoeducational intervention effect on survival in CKD, 1088–1098
 pretransplantation, effect on allograft and recipient survival, 537–549

Renal transplantation. *See also* Kidney transplant recipients
 allocation of deceased donor kidneys, 949–956
 cardiovascular disease risk and, 529–536
 darbepoetin alfa for anemia during pregnancy, 5:E81
 de novo congestive heart failure after, 720–723
 medical evaluation completion rates for, 734–745
 for older donors and recipients, 150–151
 pediatric recipient, Epstein-Barr virus associated with renal leiomyoma in, 351–355
 pretransplantation RRT effect on allograft and recipient survival, 537–549
 randomized controlled trials, Cochrane Renal Group Report on, 774–779
 sudden late gross hematuria in recipient after transplant nephrectomy, 5:E91
 vaccines for adult chronic kidney disease patients, 997–1011
 waiting list for Aboriginal hemodialysis patients, 1117–1123

Renin-angiotensin-aldosterone system
 in oligo-anuric hemodialysis patients, spironolactone effect on, 94–101
 telmisartan standard *vs.* high doses in hypertensive non-diabetic nephropathies, 1074–1079

Renovascular disease, in older patients, 149

Residual renal function, renal clearance time of uremic solutes for incident peritoneal dialysis patients, 512–519

Resistive index, relationship with arteriosclerosis in damaged kidneys, 603–609

Retina microvascular abnormalities in elderly, renal function changes and, 214–224

RIFLE classification, acute renal failure outcome in ICU, 1038–1048

Risk perception, of kidney disease, 11–17

Rosiglitazone, insulin requirement and CRP levels in diabetic PD patients, 713–719

Salmonella enteritidis CAPD-related peritonitis, in SLE patient, 2:E21

Salt and water handling, in older patients, 150

SAPS II (Simplified Acute Physiology Score II), acute renal failure outcome in ICU, 1038–1048

Screening

- for autosomal dominant polycystic kidney disease in non-symptomatic patients, 557–559

validation of depression tool for dialysis patients, 919–924

Senescence, asymmetric dimethylarginine accumulation and, 186–202

Sensitivity of identifying chronic kidney disease from Medicare claims data, 225–232

Septicemia, clinical and economic outcomes in ESRD patients on hemodialysis, 301–308

Sex. *See* Females; Males

Sexual function, asymmetric dimethylarginine accumulation and, 186–202

Simplified Acute Physiology Score II (SAPS II), acute renal failure outcome in ICU, 1038–1048

Sirolimus, thrombotic microangiopathy in patients receiving marginal kidneys, 1124–1128

Sjögren syndrome, with long-standing tubulointerstitial nephritis, secondary renal amyloidosis and, 5:E75

SLE. *See* Systemic lupus erythematosus

Smooth muscle tumor, with Epstein-Barr virus in pediatric kidney transplant recipient, 351–355

Socioeconomic status

- area level, chronic progressive kidney disease and, 203–213
- late referral for renal replacement therapy and, 881–886

Sodium balance, disorders of, 358–359

Sodium citrate

- CVVH with citrate-based replacement fluid, 908–918
- kinetics in long-term hemodialysis therapy, 903–907

Soy protein, effect on hyperlipidemic and normolipidemic hemodialysis patients, 1099–1106

Specificity of identifying chronic kidney disease, from Medicare claims data, 225–232

Spironolactone

- in oligo-anuric hemodialysis patients, effect on BP and RAAS, 94–101
- reduction of proteinuria in CKD, 45–51

Stable isotope-labeled bicarbonate, measurement of whole-body bicarbonate production in hemodialysis patients, 102–110

Staphylococcus aureus septicemia, clinical and economic outcomes in ESRD patients on hemodialysis, 301–308

Stem cell transplantation, renal response in primary systemic amyloidosis and, 270–277

Stiff-person syndrome, with minimal change nephrotic syndrome, 1:E13

Substance abuse, skipped treatments and survival in incident hemodialysis patients, 1107–1116

Survival

- analysis
- of ACS with chronic renal insufficiency, 845–855
- natural history of chronic renal failure, 863–870
- baseline comorbidity in renal transplant recipients, 136–142

renal response after high-dose melphalan with stem cell transplantation in primary systemic amyloidosis and, 270–277

Systemic fibrosis, with nephrogenic fibrosing dermopathy, 754–759

Systemic lupus erythematosus (SLE)

- anticardiolipin antibodies during immunoabsorption therapy, 446–454

CAPD-related peritonitis due to *Salmonella enteritidis* in, 2:E21

nephritis development in patient with human T-cell lymphotropic virus type I-associated myopathy, 2:E21

Systemic vasculitis, new therapeutic alternatives for, 173–185

Tamm-Horsfall protein, evidence of a fourth calcium-binding epidermal growth factor-like domain in, 52–57

Taq-Man quantitative polymerase chain reaction, in diagnosing chronic GVHD after allogeneic stem cell transplantation, 550–556

T-cell immune response, in peritoneal dialysis-related peritonitis, 328–338

Telmisartan, long-term renoprotective effects of standard vs. high doses in hypertensive nondiabetic nephropathies, 1074–1079

Tertiary care management of hypertension, 18–25

Thromboembolic complications, anticardiolipin antibodies during immunoabsorption therapy and, 446–454

Thrombolysis, outcomes for acute coronary syndrome with chronic renal insufficiency, 845–855

Thrombolytic medication, delay in time receipt among Medicare patients with kidney disease, 595–602

Thrombotic microangiopathy

- with disseminated histoplasmosis and acute tubular necrosis, 159–162
- in marginal kidneys after sirolimus use, 1124–1128

Time profiles, of renal clearances for uremic solutes in incidental peritoneal dialysis, 512–519

Transcatheter vascular embolization, for graft intolerance syndrome, incidence/efficacy of, 339–344

Transcription-mediated amplification, identification of HCV in maintenance hemodialysis patients, 290–300

Transforming growth factor β 1, degree of nephromegaly in biliary atresia, 830–836

Transfusion requirements for ARF patients, effect of erythropoietin on, 791–798

Transplantation. *See also* Renal transplantation

- liver, reversibility of nephromegaly in biliary atresia, 830–836
- racial disparities and, 760–762

Triglycerides, soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099–1106

Trimethoprim-sulfamethoxazole, for systemic vasculitis, 173–185

Troponin, in predicting coronary disease in asymptomatic CKD, 35–44

Tuberculin skin test, diagnosis of latent tuberculosis in hemodialysis, 706–712

Tuberculosis, value of anti-LAM antibody in diagnosis in hemodialysis patients, 706–712

Tubular function, comprehensive assessment in Gaucher disease, 837–844

Tubulointerstitial diseases, nephrology core curriculum, 560–572

Tubulointerstitial nephritis
and Fanconi syndrome in primary biliary cirrhosis, 3:E41
in Sjögren syndrome, secondary renal amyloidosis and, 5:E75

Tubulointerstitium, relationship of resistive index to atherosclerosis in, 603–609

Tunneled catheters, in hemodialysis patients, 501–508

Ultrasonography
assessment of severity and progression of AKPKD, 1058–1064
relationship of resistive index with arteriosclerosis in damaged kidneys, 603–609

Uremic toxin, as cardiovascular risk factor in ESRD, 186–202

Ureterosigmoidostomy, urinary tract infections and, 1030–1037

Urinalysis, performed by nephrologist vs. clinical laboratory, 820–829

Urinary diversion, urinary tract infections and, 1030–1037

Urinary tract infections, in urinary diversion patients, 1030–1037

Urinary tract obstruction, predisposition to emphysematous pyelonephritis, 432–439

Urolithiasis risk in cystic fibrosis, absorptive hyperoxaluria and, 440–445

Uromodulin disorders, novel mutation pattern in, 52–57

Vaccines, for adult patients with renal disease, 997–1011

Validation, of hemodialysis patient quality of life measured by WHOQOL-BREF(TW), 635–641

Vancomycin dosing regimen, adequacy in high-flux hemodialysis, 681–687

Vascular access
blood flow, comparison of optodilutional and ultrasound dilution methods, 933–937
blood flow evaluation by optodilutional vs. ultrasound dilution methods, 933–937
dialysis access-related infections, cardiovascular mortality and, 1149
shorter unassisted patency after angioplasty in women, 167(c)
tunneled catheters in hemodialysis patients, 501–508

Vascular dementia, in older patients, 153–154

Vascular endothelial growth factor (VEGF), mesenchymal conversion of mesothelial cells in peritoneal dialysis and, 938–948

Vascularity
calcifications in ESRD, changes after parathyroidectomy, 464–469
relationship of resistive index to atherosclerosis in damaged kidneys, 603–609

Vibrio vulnificus peritonitis, after handling seafood in patient receiving CAPD, 5:E87

Virulence factors, predisposition to emphysematous pyelonephritis, 432–439

Vitamin D
active therapy in pediatric chronic kidney disease, S1:53–63
insufficiency/deficiency, prevention and treatment in pediatric chronic kidney disease, S1:48–52

Volume status in ESRD, natriuretic peptides and, 1–10

Waiting time for transplantation, allocation of deceased donor kidneys and, 949–956

Water balance
disorders of, 359–361
physiology of, 357–358

Water deprivation test, for hypernatremia evaluation, 1150(c)

Weight loss, cardiovascular survival of hemodialysis patients and, 489–500

World Health Organization Quality-of-Life Questionnaire Brief Taiwanese version, validation of, 635–641

